The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

obolensk.ru

Founded Year

1994

Stage

Merger | Merged

Total Raised

$61.78M

About OBL Pharm

OBL Pharm engages in the development, production and promotion of modern and high-quality pharmaceuticals in accordance with GMP and ISO international standards.

OBL Pharm Headquarter Location

Building 11, 4th floor 31 Shaboloyka St

Moscow, 115162,

Russian Federation

+7 (495) 646-28-68

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing OBL Pharm

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

OBL Pharm is included in 1 Expert Collection, including Biopharma Tech.

B

Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

OBL Pharm Patents

OBL Pharm has filed 6 patents.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

6/24/2014

2/2/2016

Gastropod anatomy, Orthopedic surgical procedures, Transcription factors, Mollusc shells, Bone fractures

Grant

Application Date

6/24/2014

Grant Date

2/2/2016

Title

Related Topics

Gastropod anatomy, Orthopedic surgical procedures, Transcription factors, Mollusc shells, Bone fractures

Status

Grant

Latest OBL Pharm News

Sistema PJSFC: Sistema completes merger of OBL Pharm and Binnopharm Sistema completes merger of OBL Pharm and Binnopharm   Moscow, 14 October 2019.

Oct 14, 2019

0 Message : 14-Oct-2019 / 09:45 MSK Dissemination of a Regulatory Announcement that contains inside information according to REGULATION (EU) No 596/2014 (MAR), transmitted by EQS Group. The issuer is solely responsible for the content of this announcement. - Sistema PJSFC ("Sistema") (LSE: SSA, MOEX: AFKS), a publicly traded diversified Russian holding company, announces the completion of the merger of pharmaceutical assets JSC Pharmaceutical Enterprise Obolenskoe ("OBL Pharm") and JSC Binnopharm ("Binnopharm"). The merged company will operate under the brand Alium. As a result of Sistema's participation in an additional issue of OBL Pharm shares, Sistema's effective stake in the company increased from 12.8% to 26.3%. VTB Bank's effective stake in OBL Pharm now stands at 38.5%, while the total stake owned by the consortium of investors including the Russian Direct Investment Fund ("RDIF"), the Russia-China Investment Fund (RCIF, which was created by RDIF and China Investment Corporation) and leading Middle Eastern funds is 23.0%. Sistema paid for its additional shares of OBL Pharm using the 88.7% of Binnopharm shares that it owned. [1] The merger of OBL Pharm and Binnopharm created pharmaceuticals holding Alium, one of Russia's largest pharma companies in the commercial segment. Alium's total production area exceeds 70,000 sq m and includes four high-tech facilities in Moscow and the Moscow region. The company's diversified product portfolio comprises approximately 200 drugs used across therapeutic areas including respiratory, nervous and gastrointestinal systems, cardiology, infectious diseases and colds as well as pain relief. *** Sistema PJSFC is a publicly-traded diversified Russian holding company serving over 150 million customers in the sectors of telecommunications, high technology, financial services, retail, paper and packaging, agriculture, real estate, tourism and medical services. The company was founded in 1993. Revenue in 2018 was RUB 777.4 bn; total assets equalled RUB 1.5 trn as of 31 December 2018. Sistema's global depositary receipts are listed under the "SSA" ticker on the London Stock Exchange. Sistema's ordinary shares are listed under the "AFKS" ticker on the Moscow Exchange. Website:  www.sistema.com

  • When was OBL Pharm founded?

    OBL Pharm was founded in 1994.

  • Where is OBL Pharm's headquarters?

    OBL Pharm's headquarters is located at Building 11, 4th floor, Moscow.

  • What is OBL Pharm's latest funding round?

    OBL Pharm's latest funding round is Merger.

  • How much did OBL Pharm raise?

    OBL Pharm raised a total of $61.78M.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.